Sanofi’s $3.7B Principia buy starts to pay off with Phase III rilzabrutinib win
Data from the Phase III LUNA 3 study on Tuesday showed that Sanofi’s BTK inhibitor rilzabrutinib significantly improved durable platelet response in patients with chronic immune thrombocytopenia.